Trial
NCT03674827
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
—
Condition
Non-Small Cell Lung Cancer
Intervention
PF-06936308
Why stopped
The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology portfolio; the study was not terminated because of safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-23